巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Unicycive Therapeutics

    UNCY
    0.899
    0.090
    10.77%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Unicycive Therapeutics - 延遲價格・最後更新於 27/05 8:36
    最高位
    0.899
    最低位
    0.899
    開市價
    --
    前收市價
    0.811
    成交量(千)
    0.00
    成交額(百萬)
    0.00
    買入
    --
    賣出
    0.900
    每手股數
    --
    市值(百萬)
    13.51
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    8.730 - 0.624
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Unicycive Therapeutics
    證券代碼
    UNCY.US
    所屬板塊
    Biotechnology
    公司業務
    Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
    發行量
    14996534
    公司總部
    5150 El Camino Real, Suite A-32
    公司網址
    https://www.unicycive.com
    公司電話
    +1 650 351-4495

    一周前瞻 | 時代天使6月16日上市 聯儲局領銜央行超級周

    佟岷·
    一周前瞻 | 時代天使6月16日上市 聯儲局領銜央行超級周

    關於

    Unicycive Therapeutics(UNCY.US)所屬的行業板塊為Biotechnology。
    Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
    詳細公司背景可參考: https://www.unicycive.com